glp-1 weight loss clinical trials GLP1 agonists: current and future landscape of for patients with metabolic dysfunction GLP-1R Agonists for Weight Loss
Description
Ongoing research will be crucial in determining the full scope of their applications, but I am excited to see the potential positive role they may play in mental health care. References: Azoulay L, et al
Both options have their unique benefits and considerations, with Wegovy offering the advantage of FDA approval and standardized dosing, while compounded semaglutide provides customization and potentially lower costs
Erratum in Lancet 2019, 394, e1
Every recipe takes 2 minutes or less to prep
No new safety signals appeared between weeks 24 and 48, suggesting the medication does not cause delayed-onset problems during the first year of use
What daily habits create long-term metabolic strength
